Delivery Order 36F79724D0185-36C24526N0855
Award Date 9/9/26
Potential Completion Date 9/15/26
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on July 1, 2026, for Galafold (migalastat) 123 mg under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is Philadelphia, PA 19104. The order is due July 7, 2026. The requirement is for Galafold 123 mg capsules, an FDA-approved enzyme replacement therapy indicated for treatment of Fabry disease in veterans. Pricing is firm fixed price with no...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 7, 2026, for Galafold 123 mg under the GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB). The parent contract is a multiple-award Federal Supply Schedule vehicle (36F79724D0185) valued at $13.024 million, effective through August 31, 2029, enabling VA medical centers nationwide to procure specialized pharmaceutical products. Place of performance is Philadelphia, PA. The order is firm...
- Veterans Integrated Service Network 9 issued a delivery order to Amicus Therapeutics US, LLC on May 27, 2026, for Galafold (migalastat) 123 mg capsules with a ceiling value of $68,518.83. The order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a multiple-award GSA Schedule contract valued at $13,024,630 and effective through August 31, 2029. Place of performance is Murfreesboro, TN. The order is firm fixed price with an ultimate completion date of August...
- Veterans Integrated Service Network 7 issued a $228,396.10 delivery order to Amicus Therapeutics US, LLC on February 23, 2026, for Galafold medication under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The parent Federal Supply Schedule contract, effective through August 31, 2029, enables VISNs across the Department of Veterans Affairs to procure Galafold (migalastat) 123 mg, an FDA-approved enzyme replacement therapy for Fabry disease treatment. Place of performance is...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on November 20, 2025, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order, with no set-aside designation, represents a task order placed under Amicus Therapeutics' existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 28, 2026, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule for Galafold 123 mg. Performance is at Philadelphia, PA, with an ultimate completion date of May 4, 2026. The parent vehicle is the GSA Federal Supply Schedule contract (FSS-61-IB), a multiple-award schedule enabling VA networks nationwide to procure pharmaceutical products including enzyme replacement...
- The Department of Veterans Affairs Veterans Health Administration has awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc., to provide the specialty medication Galafold (migalastat) under the GSA's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The potential value of this delivery order is $63,268.41, and it is intended to fulfill the VA's pharmaceutical requirements to support healthcare...
- Veterans Integrated Service Network 9 issued a $68,518.83 delivery order to Amicus Therapeutics US, LLC on August 24, 2026, for emergency Galafold pharmacy drugs under the GSA Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The parent FSS contract, awarded September 1, 2024, and effective through August 31, 2029, supports pharmaceutical procurement across VA healthcare networks. Place of performance is Philadelphia, PA. The delivery order is firm fixed price with an ultimate...
- The Department of Veterans Affairs, Veterans Integrated Service Network 19, awarded a delivery order to Amicus Therapeutics US, LLC for Galafold 123 mg capsules valued at $295,018.13. This firm fixed-price delivery order, issued on November 15, 2025, with an ultimate completion date of November 14, 2026, represents a child task order under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract (36F79724D0185), valued at $13.02 million and effective through August 31,...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $18,520.05 delivery order to Amicus Therapeutics US, LLC under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for GALAFOLD specialty medication migalastat 123 mg to treat Fabry disease and will be fulfilled by Amicus Therapeutics, Inc., the parent company of Amicus Therapeutics US, LLC, with place of performance in Cranbury, New Jersey. The...